This article is more than 5 years old. Information may no longer be current.

iSTAR's MINIject shows positive 18-month results

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

iSTAR Medical’s MINIject device showed positive results in a first-in-human trial, with a mean pressure reduction of 15 mm Hg at 18 months, according to a press release.

The 18-month results of the STAR-I clinical trial are consistent with results reported at 1 year.

Nearly two-third of patients who received the MINIject device, which reduces IOP by enhancing aqueous humor outflow from the anterior chamber to the supraciliary space, were able to cease eye drop usage as well, the release said.

“We are thrilled to see MINIject’s powerful and reliable efficacy in a stand-alone procedure sustained over time, without a trade-off between safety and efficacy, and without requiring invasive follow-up procedures or surgeries,” iSTAR Medical CEO Michel Vanbrabant said in the release. “We look forward to bringing this therapeutic option in the supraciliary space to market for glaucoma patients.”